Trial Profile
A Study to Evaluate the Early Metabolic Treatment Response to Erlotinib in Patients with Advanced Non-Small-Cell-Lung-Cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Dec 2015 New trial record